Malvern, Penn.-based TetraLogic Pharmaceuticals (TLOG) announced today that it has temporarily halted its Hepatitis B (HBV) clinical trial.
The company did not respond to a request for a statement by deadline.
The Phase Ib/IIa trial of birinapant for HBV was stopped because of cranial nerve palsies seen in the first cohort.
Birinapant is an investigational SMAC-mimetic, being studied for treatment for HBV, myelodysplastic syndromes (MDS) and ovarian cancer. The compound, and SMAC-mimetics in general, are believed to disable certain pathways that allow cancer cells and some types of virally infected cells from growing.
Read more...Labels: adverse effects, birinapant, cranial nerve palsies, TetraLogic, trial halted